Gibson, Dunn & Crutcher, White & Case top MEA legal advisers in Q1-Q3 2025
Gibson, Dunn & Crutcher and White & Case have emerged as the foremost legal advisers for mergers and acquisitions (M&A)…
21 Oct 2025
ESMO 2025: Merck KGaA’s ADC leapfrogs to Phase III in colorectal cancer
Merck KGaA's antibody-drug conjugate (ADC), precemtabart tocentecan (Precem-TcT), has shown promising efficacy during an early-stage trial in heavily pre-treated colorectal cancer. Thus far in the ongoing Phase I PROCEADE-CRC-01 study…
21 Oct 2025
MSD initiates construction on $3bn Virginia drug manufacturing site
Merck & Co (MSD) has broken ground on its new pharmaceutical manufacturing Centre of Excellence in Virginia, US, amid looming tariff threats from the Trump administration. The $3bn site, which…
21 Oct 2025
Lundbeck and Contera partner for oligonucleotide-based medicines
H Lundbeck and Contera Pharma have announced a research partnership aimed at expediting the discovery as well as development of new oligonucleotide-based therapies for serious neurological conditions. The partnership seeks…
21 Oct 2025
FDA approves Roche’s Gazyva for lupus nephritis
The US Food and Drug Administration (FDA) has granted approval for Roche's Gazyva/ Gazyvaro (obinutuzumab) to treat adult patients with active lupus nephritis (LN) who are on standard therapy. The…
20 Oct 2025
FDA approves Glaukos’ Epioxa as incision-free corneal disease treatment
The US Food and Drug Administration (FDA) has approved Glaukos Corporation’s Epioxa, offering patients living with a rare corneal disease a treatment option that does not require incisions. Epioxa, which…
20 Oct 2025
ESMO 2025: J&J eyes Rybrevant indication expansion to HNSCC on Phase II victory
Johnson & Johnson’s (J&J’s) bispecific Rybrevant (amivantamab) could provide an effective, novel option for patients with head and neck squamous cell cancer (HNSCC), an expert has said. This follows the…